We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-17.39%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$155M
AUM Growth
-$33.9M
Cap. Flow
+$9.51M
Cap. Flow %
6.12%
Top 10 Hldgs %
89.26%
Holding
44
New
3
Increased
6
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$7.92M
2
SIEN
Sientra, Inc.
SIEN
+$1.55M
3
QTNT
Quotient Limited Ordinary Shares
QTNT
+$625K
4
NBIX icon
Neurocrine Biosciences
NBIX
+$469K
5
OVV icon
Ovintiv
OVV
+$391K

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$650K
2
MDVN
MEDIVATION, INC.
MDVN
+$525K
3
COLL icon
Collegium Pharmaceutical
COLL
+$362K
4
NSPR icon
InspireMD
NSPR
+$188K
5
CALA
Calithera Biosciences, Inc
CALA
+$141K

Sector Composition

Rank Sector Weight
1 Healthcare 90.48%
2 Energy 3.63%
3 Consumer Staples 1.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
26
Neurocrine Biosciences
NBIX
$17.4B
$386K 0.25%
+9,700
New +$469K
CELGZ
27
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$384K 0.25%
238,214
+24,782
+12% +$47.8K
CERS icon
28
Cerus
CERS
$631M
$377K 0.24%
83,000
– –
PXD
29
DELISTED
Pioneer Natural Resource Co.
PXD
$365K 0.23%
3,000
– –
ADXS
30
DELISTED
Advaxis Inc
ADXS
$364K 0.23%
2,373
– –
MACK
31
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$360K 0.23%
5,376
– –
RPTP
32
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$327K 0.21%
54,000
+8,000
+17% +$98K
ROKA
33
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$297K 0.19%
15,231
– –
BIIB icon
34
Biogen
BIIB
$29.5B
$292K 0.19%
1,000
– –
TTHI
35
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$261K 0.17%
145,746
– –
AGIO icon
36
Agios Pharmaceuticals
AGIO
$2.38B
$240K 0.15%
3,400
– –
NXTM
37
DELISTED
NxStage Medical Inc.
NXTM
$232K 0.15%
14,700
– –
OXFD
38
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$207K 0.13%
+15,303
New +$207K
PBYI icon
39
Puma Biotechnology
PBYI
$422M
$162K 0.1%
2,150
– –
CHRS icon
40
Coherus Oncology
CHRS
$219M
$150K 0.1%
7,500
– –
XNCR icon
41
Xencor
XNCR
$1.39B
$150K 0.1%
12,300
– –
PQUE
42
DELISTED
PETROQUEST ENERGY INC (DE)
PQUE
$143K 0.09%
122,050
– –
NSPR icon
43
InspireMD
NSPR
$33M
– –
0
– -$188K
CALA
44
DELISTED
Calithera Biosciences, Inc
CALA
– –
-985
Closed -$141K
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2015 Portfolio in Review

As of Q3 2015, Birchview Capital held 44 positions worth $155M, down 18% from $189M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Birchview Capital deployed $9.51M of net new capital in Q3 2015, opening 3 new positions and adding to 6 existing holdings. Its largest new stake was Sientra, Inc.: 6,830 shares worth $693K.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier, followed by Energy and Consumer Staples.

On the sell side, the largest reduction was Gilead Sciences, an estimated $650K trimmed.

  • Birchview Capital's largest Q3 2015 buy was Sientra, Inc.: 6,830 shares worth $693K.
  • Birchview Capital added most to Celgene Corp in Q3 2015, an estimated $7.92M increase.
  • Birchview Capital's biggest Q3 2015 reduction was Gilead Sciences, cutting an estimated $650K.
  • Birchview Capital fully exited Calithera Biosciences, Inc in Q3 2015, selling an estimated $141K.
  • Birchview Capital's ten largest holdings make up 89% of its $155M portfolio in Q3 2015.
  • Birchview Capital opened 3 new positions and closed 1 in Q3 2015.
  • Birchview Capital's portfolio value fell 18% quarter-over-quarter to $155M.

Based on Birchview Capital's 13F filing for Q3 2015, filed 6 Nov 2015.